Hospira Company Profile

✉ Email this page to a colleague

HOSPIRA has five hundred and seventeen approved drugs.

There are nine US patents protecting HOSPIRA drugs. There are seven tentative approvals on HOSPIRA drugs.

There are seventy patent family members on HOSPIRA drugs in thirty-eight countries and four hundred and twenty-two supplementary protection certificates in sixteen countries.

International Patents:	70
US Patents:	9
Tradenames:	333
Ingredients:	210
NDAs:	517
Patent Litigation for Hospira:	See patent lawsuits for Hospira
PTAB Cases with Hospira as petitioner:	See PTAB cases with Hospira as petitioner

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	INDOMETHACIN SODIUM	indomethacin sodium	INJECTABLE;INJECTION	204118-001	Apr 19, 2016	AP	RX	No	No		⤷ Sign Up				⤷ Sign Up
Hospira	CEFOTAXIME SODIUM	cefotaxime sodium	INJECTABLE;INJECTION	203132-002	Feb 19, 2016		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Hospira Inc	DOCETAXEL	docetaxel	INJECTABLE;INJECTION	022234-005	Jun 23, 2016		RX	Yes	No		⤷ Sign Up				⤷ Sign Up
Hospira	CYTARABINE	cytarabine	INJECTABLE;INJECTION	072168-001	Aug 31, 1990	AP	RX	No	Yes		⤷ Sign Up				⤷ Sign Up
Hospira Inc	AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER	amino acids; dextrose; magnesium chloride; potassium chloride; sodium chloride; sodium phosphate, dibasic, heptahydrate	INJECTABLE;INJECTION	019682-002	Nov 1, 1988		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hospira	PRECEDEX	dexmedetomidine hydrochloride	INJECTABLE;INJECTION	021038-002	Mar 13, 2013	6,716,867*PED	⤷ Sign Up
Hospira	PRECEDEX	dexmedetomidine hydrochloride	INJECTABLE;INJECTION	021038-002	Mar 13, 2013	4,910,214*PED	⤷ Sign Up
Hospira	BRETYLOL	bretylium tosylate	INJECTABLE;INJECTION	017954-001	Approved Prior to Jan 1, 1982	RE29618	⤷ Sign Up
Hospira	PRECEDEX	dexmedetomidine hydrochloride	INJECTABLE;INJECTION	021038-003	Mar 13, 2013	6,716,867*PED	⤷ Sign Up
Hospira	TRACRIUM PRESERVATIVE FREE	atracurium besylate	INJECTABLE;INJECTION	018831-001	Nov 23, 1983	4,179,507	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Injection	1 mg/mL, 50 mL vials	➤ Subscribe	2011-12-16
➤ Subscribe	Injection	4 mcg/mL, 50 mL and 100 mL vials	➤ Subscribe	2013-12-26
➤ Subscribe	Injection	100 mg/mL, 2.5 mL vials	➤ Subscribe	2007-09-24
➤ Subscribe	Injection	100 mcg/mL	➤ Subscribe	2009-04-08
➤ Subscribe	Injection	4 mcg/mL, 20 mL vials	➤ Subscribe	2015-09-30

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
China	107802624	⤷ Sign Up
Mexico	366122	⤷ Sign Up
Serbia	57346	⤷ Sign Up
Portugal	2648520	⤷ Sign Up
World Intellectual Property Organization (WIPO)	2013103378	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1224170	SPC/GB15/018	United Kingdom	⤷ Sign Up	PRODUCT NAME: NINTEDANIB, THE TAUTOMERS AND THE SALTS THEREOF, IN PARTICULAR NINTEDANIB AND PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF, SPECIFICALLY NINTEDANIB ESILATE. NINTEDANIB IS 3-Z-(1-(4-N-((4-METHYL-PIPERAZIN-1-YL)-METHYLCARBONYL)-N-METHYL-AMINO)-A; REGISTERED: UK EU/1/14/954/001 20141125; UK EU/1/14/954/002 20141125; UK EU/1/14/954/003 20141125; UK EU/1/14/954/004 20141125
0934061	PA2004017	Lithuania	⤷ Sign Up	PRODUCT NAME: PREGABALINUM ((S)-3-(AMINOMETIL)-5-METILHEKSANO RÃ»GÃ°TIS)
0984957	C300483	Netherlands	⤷ Sign Up	PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMTRIHYFRAAT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20110524
1189916	C01189916/01	Switzerland	⤷ Sign Up	PRODUCT NAME: REGADENOSON; REGISTRATION NO/DATE: SWISSMEDIC 66137 28.07.2017
2365988	2018C/006	Belgium	⤷ Sign Up	PRODUCT NAME: PATIROMER SORBITEX CALCIUM OF EERDER WELK ZOUT OF AFGELEIDE ERVAN; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.